A detailed history of Nisa Investment Advisors, LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 677 shares of SWTX stock, worth $24,094. This represents 0.0% of its overall portfolio holdings.

Number of Shares
677
Previous 642 5.45%
Holding current value
$24,094
Previous $24,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$32.04 - $42.76 $1,121 - $1,496
35 Added 5.45%
677 $21,000
Q2 2024

Jul 19, 2024

BUY
$36.06 - $47.62 $2,596 - $3,428
72 Added 12.63%
642 $24,000
Q1 2024

May 01, 2024

BUY
$36.5 - $52.5 $2,117 - $3,045
58 Added 11.33%
570 $28,000
Q4 2023

Jan 25, 2024

SELL
$18.94 - $37.24 $24,811 - $48,784
-1,310 Reduced 71.9%
512 $18,000
Q3 2023

Nov 02, 2023

BUY
$23.12 - $31.38 $23 - $31
1 Added 0.05%
1,822 $42,000
Q2 2023

Aug 11, 2023

BUY
$23.15 - $32.71 $486 - $686
21 Added 1.17%
1,821 $47,000
Q4 2022

Feb 02, 2023

SELL
$21.73 - $28.72 $152 - $201
-7 Reduced 0.39%
1,800 $47,000
Q3 2022

Nov 07, 2022

BUY
$24.1 - $39.66 $650 - $1,070
27 Added 1.52%
1,807 $43,000
Q2 2022

Aug 03, 2022

BUY
$18.36 - $60.07 $16,891 - $55,264
920 Added 106.98%
1,780 $44,000
Q1 2022

Apr 29, 2022

SELL
$48.97 - $65.46 $20,567 - $27,493
-420 Reduced 32.81%
860 $49,000
Q4 2021

Feb 03, 2022

SELL
$53.3 - $75.84 $34,112 - $48,537
-640 Reduced 33.33%
1,280 $71,000
Q2 2021

Aug 06, 2021

BUY
$67.45 - $85.63 $28,329 - $35,964
420 Added 28.0%
1,920 $158,000
Q4 2020

Jan 25, 2021

BUY
$48.36 - $77.92 $24,180 - $38,960
500 Added 50.0%
1,500 $109,000
Q3 2020

Oct 20, 2020

BUY
$36.14 - $51.99 $36,140 - $51,990
1,000 New
1,000 $48,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.22B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.